Immune-mediated disorders causing bleeding or thrombosis in lymphoproliferative diseases

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Malignant lymphomas are associated with significant bleeding and thrombosis risks.
• These complications arise from direct lymphoma effects or immune-mediated paraneoplastic phenomena.
• Immune-mediated disorders are the most common cause of paraneoplastic bleeding in lymphoma patients.

Purpose of the Study:

• To review the spectrum of bleeding and thrombosis complications in malignant lymphomas.
• To highlight the role of immune-mediated paraneoplastic disorders in these complications.
• To discuss the relationship between lymphoma characteristics and these hematologic disorders.

Main Methods:

• Literature review of paraneoplastic immune-mediated disorders in malignant lymphomas.
• Analysis of common and rare bleeding conditions associated with lymphoma.
• Discussion of thrombosis-predisposing conditions, including antiphospholipid antibodies.

Main Results:

• Key immune-mediated bleeding disorders include autoimmune thrombocytopenia, acquired hemophilia A, and acquired von Willebrand syndrome.
• Less common bleeding conditions involve deficiencies in factors X, V, XI, XII, or prothrombin, and acquired thrombasthenia.
• Antiphospholipid antibodies predispose to venous and arterial thrombosis; hyperlipidemic xanthomatosis exclusively to arterial thrombosis.

Conclusions:

• Successful treatment of the underlying lymphoma frequently leads to sustained resolution of associated immune-mediated bleeding disorders.
• There is minimal correlation between lymphoma histology/aggressiveness and the type/prevalence of immune-mediated conditions.
• Understanding these paraneoplastic phenomena is crucial for managing lymphoma patients.